About Aisling Capital
Aisling Capital is a private equity firm founded in 2000. It is primarily based in New York City, United States. In the last 12 months, it has participated in 1 funding round.
Overall Aisling Capital portfolio has seen 46 IPOs and 59 acquisitions, namely BridgeBio, Gilead and IQVIA. A lot of funds co-invest with Aisling Capital, with names like Orbimed sharing a substantial percentage of its portfolio.
Aisling Capital has a team of 8 people, including 1 partner.
Key Metrics
Aisling Capital's Portfolio
They have invested in a total of 144 companies. Their most recent investment was in Claris Bio (Series B round) on Jul 28, 2026. Here is the most recent investment by Aisling Capital:Date | Company | Round | Amount | Co-Investors |
|---|---|---|---|---|
Jul 28, 2026 | Series B | 5001 | ||
Aug 22, 2025 | Series C | 4853 | ||
Aug 21, 2025 | Series A | 4397 | ||
Dec 19, 2024 | Post IPO | 1743 |
Here is the portfolio snapshot of Aisling Capital:
Investments by Year
The maximum number of investments were made in 2022
Team profile of Aisling Capital
Aisling Capital has a team of 8 members including 1 Partner and 3 Principals located in United States. Aisling Capital's team does not sit on the board of any company as of now.Here is a list of all team members in Aisling Capital:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | New York City | - | - | |
Principal | New York City | - | - | |
Principal | New York City | - | - | |
Principal | New York | - | - | |
Associate | New York City | - | - | |
Associate | New York | - | - | |
Analyst | New York | - | - | |
Analyst | Vidor | - | - |
Co-investors of Aisling Capital
Over the past 26 years, 168 investors have co-invested in Aisling Capital's portfolio companies.
- Top Co-investors of Aisling Capital: 168 investors entered a company along with Aisling Capital. These include investors like Orbimed (8 companies).
Aisling Capital News
•
Claris collects $118M to take eye drop into pivotal testing next year - Endpoints NewsGoogle•Jul 28, 2026•Claris Bio, Sofinnova Investments, Novo Holdings, Aisling Capital and 5 others
•
Aisling Capital Invests $762,000 in OnKure TherapeuticsMarketBeat•Apr 03, 2025•OnKure Therapeutics, Aisling Capital
•
BridgeBio Launches Precision Oncology Spinoff With $200M in FundingPrecision Oncology News•May 02, 2024•BridgeBio, Omega Funds, Deerfield, Google Ventures and 8 others
•
Bicara raises $165m to advance cancer therapyPharmaceutical Technology•Dec 12, 2023•Braidwell, TPG, Deerfield, Fairmont and 4 others
•
Bicara Therapeutics Raises $108 Million in Series B Financing for Cancer TreatmentsSilicon Valley Journals•Dec 12, 2023•Bicara Therapeutics, Red Tree Venture Capital, RA Capital Management, F-Prime Capital and 12 others
•
UK-based COMPASS Pathways secures €261.8M to advance mental health solutionsSilicon Canals•Aug 17, 2023•COMPASS Pathways, TCG Crossover, Aisling Capital, Vivo Capital and 10 others
•
Garuda Therapeutics Raises $62M in Series B FinancingFinSMEs•Feb 08, 2023•Garuda, Northpond Ventures, Orbimed, Cormorant Capital and 5 others
•
•
With $1B already in for Dren Bio, Pfizer adds to pile in $65M financingFierce Biotech•Jun 14, 2022•Dren Bio, Pfizer, Aisling Capital, HBM Healthcare Investments and 8 others
•
Shorla Oncology Appoints Dennis Purcell as Chairman of the Board of DirectorsBusiness Wire•Mar 29, 2022•Shorla Oncology, Aisling Capital
